Faricimab - CISMeF

Preferred Label : Faricimab;

NCIt synonyms : Faricimab-svoa;

NCIt definition : A humanized bispecific antibody targeting both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), that is used for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema. Upon intravitreal administration, faricimab targets and binds to both VEGF-A and Ang-2, and prevents VEGF-A- and Ang-2-mediated signaling. The inhibition of VEGF-A-mediated signaling decreases endothelial cell proliferation, neovascularization and vascular permeability. The inhibition of Ang-2-mediated signaling improves vascular stability and desensitizes blood vessels to the effects of VEGF-A. VEGF and Ang-2, upregulated in some eye diseases, play important roles in pathological neovascularization and increased vascular permeability and inflammation, which may lead to vision loss.;

UNII : QC4F7FKK7I;

CAS number : 1607793-29-2;

Drug name : Vabysmo;

Molecule name : RO 6867461; RO-6867461; RG 7716; RG-7716;

NCI Metathesaurus CUI : CL1412159;

Origin ID

C174885;

UMLS CUI

C5139890;

Currated CISMeF NLP mapping
- Faricimab [SMS substance]
- faricimab [MeSH concept]
- faricimab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- faricimab [MeSH Supplementary Concept]
- faricimab [ATC Code]
Validated automatic mappings to BTNT
- faricimab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Angiopoietin-2 [NCIt concept]
- Vascular Endothelial Growth Factor A [NCIt concept]

Keyword's position in hierarchy(ies) :

Details

Main resources

You can consult :